N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds...

Details N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds... N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds...

1999-02-24

2001-03-27

Geist, Gary (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S562000, C560S012000, C562S430000, C562S442000

Reexamination Certificate

active

06207709

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention refers to the use in the prevention and/or treatment of neurodegenerative diseases, such as, for example, Huntington's chorea, Alzheimer's disease, dementia caused by aquired immunodeficiency syndrome (AIDS), infarctual dementia, cerebral ischemia, cerebral hypoxia, Parkinson's disease, epilepsy, head and spinal cord injury, amyotrophic lateral sclerosis, glaucoma/retinopathy, infections and inflammations of the brain, of N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid derivatives which act as inhibitors of kynurenine-3-hydroxylase (KYN-3-OHase), the enzyme which forms part of the metabolic pathway of kynurenine.
A second object of this invention is directed to a restricted class of the above N-substituted-2-amino-4-oxo-4-phenyl-butanoic acid derivatives as novel compounds, either as single enantiomers or as mixture of enantiomers, to their pharmaceutically acceptable salts, to a process for their preparation, and to pharmaceutical compositions containing them.
2. Description of the Background
In the central nervous system (CNS) the metabolism of tryptophan is well known to result largely in the production of indolamines such as the neurotransmitter serotonin, while in the periphery most of non-peptide tryptophan utilisation is along the kynurenine pathway, ultimately leading to the formation of nicotinamide adenine dinucleotide (NAD) (FIG.
1
). The legend to
FIG. 1
is to be found on the last page of the experimental part. In the last decade several lines of evidence have demonstrated that two intermediates of the kynurenine metabolism, quinolinic acid (QUIN) and kynurenic acid (KYNA), when injected in the CNS, act as a neurotoxin and as a neuroprotectant, respectively. Consequently, the demonstration that these two metabolites of the kynurenine pathway (unable to cross the blood brain barrier), are normal constituents of the mammalian brain, has suggested the existence of this pathway within the CNS and proposed the involvement of QUIN and KYNA in brain physiology and pathology (Stone T. W., Pharmacol. Rew., (1993), 310-379). Both QUIN and KYNA are able to interact with the ionotropic excitatory amino acid receptors. In particular, QUIN is a highly selective agonist at N-methyl-D-aspartate (NMDA) receptor (Stone T. W., Eur. J. Pharmacol., 72, (1981) 411-412), whereas KYNA is a broad spectrum antagonist of the ionotropic excitatory aminoacid receptors, preferentially acting at the glycine co-agonist site of the NMDA receptor (J. Neurochem., 52, (1989) 1319-1328). In vitro studies have demonstrated that the exposure of neuronal cell cultures to relatively low QUIN concentrations are neurotoxic either when applied over a prolonged period of time or in combination with glutamate (Schurr A., Brain Res., 568, (1991) 199-204). In vivo QUIN has been shown to produce convulsions and axon sparing lesions that mimic the nerve cell loss described in human neurodegenerative disorders (Schwarcz R., Science, 219, (1983) 316-318). Moreover an increase in QUIN production has been demonstrated in post-ischemic gerbil brain (Saito K., J. Neurochem., 60, (1993) 180-192), following spinal cord trauma in rats (Stokes B. T., Brain Res., 633, (1994) 348-352) and in guinea pig (Blight A. R., Brain Res., 632, (1993) 314-316), and, finally, in a model of experimental allergic encephalomyelitis (Flagan E. M., J. Neurochem., 64, (1995) 1192-1196). On the other hand, KYNA has shown anticonvulsant and neuroprotective properties in several animal models (Stone T. W. Pharmacol.Rev.45,(1993) 309-379), and, additionally, the experimentally-evoked rise of KYNA concentrations is capable to elicit neuroprotection and seizures reduction (Nozaki K., J. Cereb. Blood Flow Metab., (1992), 12, 400-407; Russi P., J. Neurochem., 59, (1992) 2076). Notably, KYNA when co-injected with QUIN is able to prevent the excitotoxic neuronal damage evoked by the neurotoxin (Foster A. C., Neurosci. Lett., 48, (1984) 273-278). These data taken together suggest that KYNA may act as the brain's own defence against detrimental events, such as excitotoxicity and seizures, leading to pathological situations (Schwarcz R., Neurotoxin and neurodegenerative disease, Ann. N.Y.Sci., 140, vol. 648, 1992). It follows that pharmacological interventions aimed at increasing KYNA formation and/or blocking QUIN synthesis can be useful in the treatment of excitotoxic brain diseases. In the Kynurenine pathway (see FIG.
1
), KYN-3-OHase is the first enzyme involved in the formation of QUIN from kynurenine. Pharmacological agents acting as inhibitors of this enzyme able to block the metabolism toward QUIN and, at the same time, to increase KYNA formation, can be useful as neuroprotective agents in the prevention and/or treatment of all the neurodegenerative pathologies involving quinolinic acid or excessive activation of neurotransmission mediated by excitatory amino acid (EAA) receptors.
There is therefore a need to find pharmacological substances which can be useful as neuroprotective agents by means of their activity as inhibitors of the enzyme KYN-3-OHase. The present invention fulfills such a need.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of formula (I)
wherein
each of the groups X and Y is, independently, hydrogen; halogen; nitro; C
1
-C
6
alkyl; C
2
-C
4
alkenyl; C
2
-C
4
alkynyl; C
1
-C
6
alkoxy; C
1
-C
6
alkylthio; SOR
2
or SO
2
R
2
in which R
2
is C
1
-C
6
alkyl, phenyl or benzyl; or SO
2
N(R
3
)
2
in which each of the groups R
3
is, independently, hydrogen, C
1
-C
6
alkyl, C
2
-C
4
alkenyl, C
2
-C
4
alkynyl, phenyl or benzyl;
R is hydroxy; —OR
5
in which R
5
is C
1
-C
6
alkyl, C
2
-C
4
alkenyl, C
2
-C
4
alkynyl or benzyl; —N(R
3
)
2
or —N(R
3
)OR
3
in which each of R
3
is as defined above;
w is —COOR
4
, —COR
4
or —SO
2
R
4
in which R
4
is C
1
-C
6
alkyl, an optionally substituted C
2
-C
4
alkenyl, an optionally substituted phenyl or benzyl; —CONHR
5
or —CSNHR
5
in which R
5
is as defined above; trichloroacetyl; or trifluoroacetyl; and the pharmaceutically acceptable salts thereof, for use as a medicament, in particular as Kynurenine 3-hydroxylase inhibitors.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
A preferred class of compounds of formula (I) are those wherein
each of the groups X and Y is, independently, hydrogen; halogen; nitro; C
1
-C
6
alkyl; C
1
-C
6
alkoxy; C
1
-C
6
alkylthio; SOR
2
or SO
2
R
2
in which R
2
is C
1
-C
6
alkyl, phenyl or benzyl; SO
2
N(R
3
)
2
in which each of the groups R
3
is, independently, hydrogen, C
1
-C
6
alkyl, C
2
-C
4
alkenyl, C
2
-C
4
alkynyl, optionally substituted phenyl or benzyl;
R is hydroxy;
W is —COOR
4
, —COR
4
or —SO
2
R
4
in which R
4
is C
1
-C
6
alkyl, an optionally substituted C
2
-C
4
alkenyl, an optionally substituted phenyl or benzyl, trichloroacetyl or trifluoroacetyl; and the pharmaceutically acceptable salts thereof.
Examples of specific compounds of formula (I) are the following:
N-methylsulfonyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′-chlorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′-fluorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′,4′-difluorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′-chloro-4′-methoxyphenyl)-butanoic acid;
N-acetyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3′-fluoro-4′-methoxyphenyl)-butanoic acid;
N-benzoyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)-butanoic acid;
N-methoxycarbonyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)-butanoic acid;
N-benzyloxycarbonyl-2-amino-4-oxo-4-(3′,4′-dichlorophenyl)-butanoic acid; either as single enantiomers or as mixture of enantiomers and the pharmaceutically accepta

Affiliated with

Also associated with

Rating

N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compounds... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2440133